ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Antimicrobial resistance and carbapenemase production among gram-negative bacteria in a newly established hospital.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Comparative Analysis of Antimicrobial Resistance Profiles in Enterobacteriaceae Isolates From Outpatient Carriages and Clinical Infections in an Urban Setting.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance among Gram-negative bacteria, particularly carbapenemase production, is an increasing global public health concern. This retrospective study aimed to compare community-acquired and hospital-acquired Gram-negative infections and to evaluate antimicrobial resistance patterns, with a particular focus on carbapenemase production, in a newly established regional hospital in Turkey. A total of 437 non-duplicate Gram-negative isolates recovered between January and December 2025 were included and classified as community-acquired or hospital-acquired according to Centers for Disease Control and Prevention criteria. Antimicrobial susceptibility testing was performed using the disc diffusion method and interpreted according to EUCAST guidelines, while carbapenemase production was assessed using the NG-Test CARBA 5 assay. Of the isolates, 370 (84.66%) were community-acquired, and 67 (15.33%) were hospital-acquired. Escherichia coli was the predominant pathogen in community-acquired infections, whereas Klebsiella pneumoniae and Pseudomonas aeruginosa were most frequently isolated from hospital-acquired infections. Community-acquired isolates showed high susceptibility to carbapenems, aminoglycosides, and nitrofurantoin, while hospital-acquired isolates exhibited significantly higher resistance to β-lactams and fluoroquinolones. Carbapenem resistance was mainly observed among hospital-acquired isolates, particularly K. pneumoniae and the Enterobacter cloacae complex. Carbapenemase production was detected predominantly in hospital-acquired isolates, with OXA-48-like and NDM enzymes being the most common, although sporadic carbapenemase-producing community-acquired isolates were also identified. The early detection of multidrug-resistant Gram-negative bacteria, including carbapenemase producers, shortly after hospital opening underscores the necessity of early antimicrobial resistance surveillance and robust infection prevention and control strategies.
Indexed as
Identifiers
41784697What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.